Multicenter Observational Study on Screening for Cancer and Predicting Postoperative Recurrence Using Peripheral Blood Methylated DNA Analysis for Biomarker Discovery

Multicenter Observational Study on Screening for Cancer and Predicting Postoperative Recurrence Using Peripheral Blood Methylated DNA Analysis for Biomarker Discovery - SETOUCHI-II

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055029

Enrollment

2000

Registered

2024-09-01

Start date

2024-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Cases where "cancer screening" is conducted through imaging or endoscopic examinations. 2) Cases for which written consent has been obtained from the patient or a legally authorized representative. 3) Cases judged to have a survival prognosis of more than one year from the date of registration.

Exclusion criteria

Exclusion criteria: 1) Cases deemed inappropriate for participation in this study by the attending physician.

Design outcomes

Primary

Measure	Time frame
To verify whether "cancer screening" is possible by detecting ccfDNA and leukocyte DNA methylation in blood from patients undergoing upper and lower endoscopy and surgical procedures (benign and malignant diseases).	—

Secondary

Measure	Time frame
To test whether the detection of ccfDNA and leukocyte DNA methylation in postoperative blood of patients undergoing surgery for malignant diseases can be used to predict recurrence after curative resection. To test whether the detection of ccfDNA and leukocyte DNA methylation in the blood of benign disease cases can be used to predict malignancy before the patient develops malignancy (preemptive medicine).	—

Measure

Time frame

To test whether the detection of ccfDNA and leukocyte DNA methylation in postoperative blood of patients undergoing surgery for malignant diseases can be used to predict recurrence after curative resection. To test whether the detection of ccfDNA and leukocyte DNA methylation in the blood of benign disease cases can be used to predict malignancy before the patient develops malignancy (preemptive medicine).

—

Countries

Japan

Contacts

Public ContactTakeshi Nagasaka

Kawasaki Medical School Advanced Oncology

takeshin@med.kawasaki-m.ac.jp0864621111

Outcome results